PURPOSE: This randomized clinical trial is studying how well diet works in altering disease progression in patients with prostate cancer on active surveillance. We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT.
With IMRT, a number of x-ray beams are used to shape the radiation to the prostate. PBT is another type of external radiation treatment for prostate cancer that is used in a few centers in the United States. Protons are tiny particles with positive charge that can be controlled to travel a certain distance and stop. We are checking for circulating tumor cells at baseline, one month and at progression of disease.
This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. The goal of this study is to improve detection of prostate cancers that require treatment.
Achieving the aims of this research will lead to better care and reduced anxiety for patients suspected of aggressive prostate cancer.
The purpose of this study is to evaluate the safety and effectiveness of a moderate hypofractionation regimen of proton beam therapy with same time treatment of the prostate, seminal vesicles, and the regional pelvic nodes for patients who have clinically localized, high risk or unfavorable intermediate risk prostate cancer. The purpose of this study is to test the safety of cabazitaxel, mitoxantrone, and prednisone CAMP in combination at different dose levels and to determine the highest dose that does not cause bad side effects.
The primary purpose of this study is to assess progression-free survival of men who have oligometastatic prostate cancer after randomization to stereotactic ablative radiation therapy SABR versus SABR and Radium The purpose of this study is to evaluate the safety and effectiveness of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy NHT in men with metastatic castration-resistant prostate cancer mCRPC who have previously been treated with one, and only one, NHT for their prostate cancer disease.
The purpose of this study is to examine bladder filling for radiation treatment to the prostate, and to evaluate how bladder fullness changes daily during radiation treatment.
The purpose of this study is to see if MR-guided laser ablation can effectively treat prostate tumor recurrences. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or The purpose of this study is to assess the accuracy of DNA marker candidates individually and in combination assayed from urine and prostatic fluid collected following digital prostate massage for detection of prostate cancer.
The purpose of this study is to determine if treatment with androgen deprivation therapy ADT plus apalutamide before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response pCR rate and metastasis-free survival MFS , as compared to ADT plus placebo.
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
The purpose of this study is to determine whether men treated for localized prostate cancer adhere to a long-term months-years daily intermittent fasting regimen, and to measure the levels of metabolic and prostate-cancer derived microparticles in the serum of men that practice a daily intermittent fasting regimen after treatment for localized, high-risk prostate cancer. The purpose of this study is to determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation therapy SRT with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival bPFS compared to SRT alone.
Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy 28 treatments alone to proton therapy with androgen suppression therapy.
Castration-resistant prostate cancer patients with rising prostatic specific antigen PSA are eligible for this study. Patients with. The purpose of this study is to evaouate how well standard systemic therapy with or without definitive treatment prostate removal surgery or radiation therapy works in treating participants with prostate cancer that has spread to other places in the body. Tissue and blood will be collected before treatment.
If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery.
Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur. The purpose of this study is to assess the safety and efficacy of pembrolizumab MK combination therapy in patients with metastatic castrate resistant prostate cancer mCRPC.
Outcome measures will be assessed individually for each cohort. The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone AA-P compared to AA-P plus placebo. The purpose of this study is to identify DNA methylation genetic markers in non-cancerous prostate tissue, and compare with the markers previously found to be in prostate cancer tissue.
This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer. The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. The purpose of this research is to see if MR-guided cryoablation can effectively treat prostate tumor recurrences.
The aims of this study are to evaluate the prevalence of vitamin D deficiency among AA prostate cancer patients and to determine the deficits in immunity associated with vitamin D deficiency. Also, we will evaluate whether the peripheral blood immune cell function is different in AA prostate cancer patients with metastatic disease as compared with those with localized disease.
See Contacts and Locations. Study Description. This is a phase 3, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide Erleada in men on active surveillance for prostate cancer. MedlinePlus related topics: Prostate Cancer. Drug Information available for: Apalutamide. FDA Resources. Arms and Interventions. Participants will receive apalutamide mg 4 x 60 mg tablets orally once a day for up to 3 months followed by placebo to match apalutamide 4 tablets orally once a day for up to 3 months.
Participants will receive placebo to match apalutamide 4 tablets orally once a day for up to 6 months. Outcome Measures. Eligibility Criteria.
Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: signed informed consent. Exclusion Criteria: Contraindications to apalutamide or its excipients. Pelvic metalwork interfering with MRI prostate interpretation. Any prior use of androgen deprivation therapy or androgen receptor targeting agents not including 5-alpha reductase inhibitors.
Any prior systemic therapy for prostate cancer. Radiation therapy is getting more precise, enabled by technologies that make it easier to kill tumors while sparing their surrounding tissues. Some newer therapies are even given intravenously instead of by machines, and they deliver radiation particles directly to the cancer cell itself.
One of these new therapies — a sort of smart bomb targeted at malignant cells — is now generating promising data for men with the most aggressive prostate cancer. Healthy prostate cells don't contain PSMA, or do at very low levels.
But the ability to detect very small amounts of metastatic prostate cancer could help doctors and patients make better-informed treatment decisions. For example, if metastatic cancer is found when a man is first diagnosed, he may choose an alternative to surgery because the cancer has already spread. Or doctors may be able to treat cancer recurrence—either in the prostate or metastatic disease—earlier, which may lead to better survival.
Such imaging may eventually be able to help predict who needs more aggressive treatment—such as radiation therapy in addition to surgery—after diagnosis. Treatments for prostate cancer that has not spread elsewhere in the body are surgery or radiation therapy RT , with or without hormone therapy.
Active surveillance is also an option for men who have a low risk of their cancer spreading. Over the last few years, several new approaches to hormone therapy for advanced or metastatic prostate cancer have been approved for clinical use. Many prostate cancers that originally respond to treatment with standard hormone therapy become resistant over time, resulting in castrate-resistant prostate cancer CRPC.
Three new drugs have been shown to extend survival in men with CRPC. All three block the action of hormones that drive CRPC:. The survival benefit for these drugs has been seen regardless of whether men have previously received chemotherapy. In addition, both enzalutamide and the drug apalutamide Erleada have all been shown to decrease the risk of metastases in men with CRPC that has not yet spread to other parts of the body.
Darolutamide has been shown to increase the amount of time men live without their cancer metastasizing. Abiraterone, apalutamide, and enzalutamide have been shown to improve the survival of men with metastatic castrate-sensitive prostate cancer when added to standard hormone therapy. Scientists are continuing to study novel treatments and drugs, along with new combinations of existing treatments, in men with metastatic CRPC.
Immunotherapies are treatments that harness the power of the immune system to fight cancer. These treatments can either help the immune system attack the cancer directly or stimulate the immune system in a more general way.
Vaccines and checkpoint inhibitors are two types of immunotherapy being tested in prostate cancer. Treatment vaccines are injections that stimulate the immune system to recognize and attack a tumor.
One type of treatment vaccine called sipuleucel-T Provenge is approved for men with few or no symptoms from metastatic CRPC. An immune checkpoint inhibitor is a type of drug that blocks proteins on the immune cells, making the immune system more effective at killing cancer cells.
A checkpoint inhibitor called pembrolizumab Keytruda has been approved for the treatment of tumors, including prostate cancers, that have specific genetic features. Pembrolizumab has also been approved for any tumor that has metastasized and has a high number of genetic mutations. But relatively few prostate cancers have these features, and prostate cancer in general has largely been resistant to treatment with checkpoint inhibitors and other immunotherapies, such as CAR T-cell therapy.
Research is ongoing to find ways to help the immune system recognize prostate tumors and help immune cells penetrate prostate tumor tissue. Studies are looking at whether combinations of immunotherapy drugs, or immunotherapy drugs given with other types of treatment, may be more effective in treating prostate cancer than single immunotherapies alone. Some prostate tumors have genetic defects that limit their ability to repair DNA damage. Two PARP inhibitors, olaparib Lynparza and rucaparib Rubraca , have been approved for some men whose prostate cancer has metastasized , and whose disease has stopped responding to standard hormone treatments.
Scientists are also developing targeted therapies based on PSMA, the same protein that is being tested for imaging prostate cancer.
For treatment, the molecule that targets PSMA is chemically linked to a radioactive compound. This new compound can potentially find, bind to, and kill prostate cancer cells throughout the body. In a recent clinical trial, men with a type of advanced prostate cancer who received a PSMA-targeting drug lived longer than those who received standard therapies. Ongoing and planned clinical trials are testing PSMA-targeting drugs in patients with earlier stages of prostate cancer, and in combination with other treatments, including targeted therapies like PARP inhibitors and immunotherapy.
Research is uncovering more information about the genetic changes that happen as prostate cancers develop and progress. Although early-stage prostate cancer has relatively few genetic changes compared with other types of cancer, researchers have learned that metastatic prostate cancers usually accumulate more mutations as they spread through the body. Such trials enroll participants based on the mutations found in their cancer, not where in the body the cancer arose.
In the NCI-MATCH trial , a high percentage of enrolled men with advanced prostate cancer had mutations that could potentially be targeted with investigational drugs. Many NCI-funded researchers working at the National Institutes of Health campus, as well as across the United States and world, are seeking ways to address prostate cancer more effectively.
Some of this research is basic, exploring questions as diverse as the biological underpinnings of cancer and the social factors that affect cancer risk. And some is more clinical, seeking to translate basic information into improving patient outcomes. NCI funds and oversees both early- and late-phase clinical trials to develop new treatments and improve patient care.
Trials are available for prostate cancer prevention , screening , and treatment. Menu Contact Dictionary Search. Understanding Cancer. What Is Cancer? Cancer Statistics. Cancer Disparities. Cancer Causes and Prevention.
0コメント